secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2025-01-06T23:59:59+00:00
Accession:  0001193125-25-002189
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology CMO Stephen Dale resigns; Mollie Leoni named CMO, Francis Burrows CSO
--------------------------------------------------------------------------------

- Stephen Dale, M.D. resigned as CMO effective Jan 2, 2025 due to personal health challenges.
- Settlement provides 18 months base salary, 2024 bonus, and extended option exercise through Mar 31, 2026.
- Mollie Leoni, M.D. appointed Chief Medical Officer on Jan 2, 2025.
- Francis Burrows, Ph.D. appointed Chief Scientific Officer on Jan 2, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312525002189/0001193125-25-002189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312525002189/d912671d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-002189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer